Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
Abstract Background Pulmonary hypertension is a deadly complication of bronchopulmonary dysplasia, the most common pulmonary morbidity of prematurity. Despite these catastrophic consequences, no evidence-based therapies are available for the prevention of pulmonary hypertension in this population. S...
Main Authors: | Simone Schneider, Mary Bailey, Tracy Spears, Charles R. Esther, Matthew M. Laughon, Christoph P. Hornik, Wesley Jackson |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | BMC Pediatrics |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12887-020-02453-7 |
Similar Items
-
Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators—The Pediatric Cardiologist Point of View
by: Anna Migdał, et al.
Published: (2021-04-01) -
The clinical case of sildenafil administration in a very premature infant with pulmonary hypertension
by: Galina A. Alyamovskaya, et al.
Published: (2015-02-01) -
Bronchopulmonary dysplasia in critically ill infants : incidence and predictive factors
by: Tan, Sanzhi, et al.
Published: (2014) -
Predictors of Bronchopulmonary Dysplasia Formation
by: Ye.N. Okhotnikova, et al.
Published: (2013-11-01) -
Sildenafil Use in the Treatment of Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension: A Case Series
by: Amna Qasim, et al.
Published: (2018-10-01)